Osteopontin is a marker for cancer aggressiveness and patient survival.

ABSTRACT:

Background

Only a fraction of molecular cancer markers identified in the scientific literature have found clinical use. Specifically, few predictors of invasiveness are established in diagnostics. Meta-analysis is a valuable tool for biomarker validation. Here, we evaluate Osteopontin as a marker for tumor aggressiveness (grade, stage, early progression) and patient survival.

Methods

Publications through 2008 with the keywords 'osteopontin AND cancer' were retrieved. Titles and abstracts were screened for studies presenting original data on human subjects. This left 228 publications for data extraction. We applied categorical data analysis for testing the relationship between Osteopontin and a clinical variable.

Results

Osteopontin ranks correlated with lower overall

SUBMITTER: Weber GF 

PROVIDER: S-EPMC2966627 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature